OA
AQST icon

Operose Advisors’s Aquestive Therapeutics AQST Stock Holding History

Operose Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.1K Hold
13,000
– – 0.01% 310
2026
Q1 		$54K Hold
13,000
– – 0.01% 279
2025
Q4 		$84K Hold
13,000
– – 0.02% 241
2025
Q3 		$72.7K Buy
+13,000
New +$56.2K 0.02% 230

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Operose Advisors's AQST Position: Q2 2026 in Review

Operose Advisors held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 13,000 shares worth $54.1K. The position accounts for 0.01% of the portfolio, ranked #310.

Operose Advisors first reported a position in AQST in Q3 2025 and has held it in 4 quarters since. The position peaked at $84K in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Operose Advisors held 13,000 shares of Aquestive Therapeutics worth $54.1K as of Q2 2026.
  • Operose Advisors left its Aquestive Therapeutics share count unchanged in Q2 2026.
  • Aquestive Therapeutics made up 0.01% of Operose Advisors's portfolio in Q2 2026, its #310 holding.
  • Operose Advisors first reported a position in Aquestive Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Operose Advisors's Aquestive Therapeutics position peaked at $84K in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Operose Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.